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Chemotherapy  may  be indicated  in  head  and  neck  cancer:  as induction,  associated  with  radiation  therapy,
or as  a palliative  solution,  in case  of  local  or locoregional  progression  if surgery  and  radiation  therapy  are
contraindicated,  and/or  in  case  of  metastatic  progression.  The  most  frequently  used  anticancer  agentsare pathway
are platins,  antimetabolites  (5-ﬂuorouracil,  methotrexate)  and taxanes.  For  several  years  now,  in  some
indications,  chemotherapy  may  be  associated  with  targeted  anti-EGFR  antibody  therapy.  Prescription  of
chemotherapy  and  follow-up  in  head  and  neck  cancer  requires  particular  attention  due  to comorbidi-
ties  related  to alcohol  abuse  and  smoking  and  frequent  denutrition.  Management  thus  requires  close
cooperation  between  the  ENT  physician,  medical  oncologists  and  radiation  oncologists.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
The present guidelines, drawn up by a work group for the
rench ENT Society (Société Franc¸ aise d’Oto-Rhino-Laryngologie
SFORL]), are intended to deﬁne the essential steps in the primary
are pathway of patients being treated by chemotherapy for
ead and neck cancer. They are derived from a review of the
iterature and graded A, B or C according to decreasing level of
vidence, following the guide to literature analysis and guide-
ines grading published by the French health accreditation and
valuation agency, ANAES, in January 2000 (Table 1). Surgery,
adiation therapy and chemotherapy are the three reference
reatments in head and neck cancer [1] (level of evidence 4).
hemotherapy may  be indicated as induction (“neo-adjuvant”
hemotherapy) [2] (level of evidence 1), notably for organ sparing
larynx, hypopharynx); in association with radiation therapy [3]
level of evidence 1), sequentially and/or concomitantly; or as
 palliative solution, in case of local or locoregional progression
f surgery and radiation therapy are contraindicated, and/or in
ase of remote (metastatic) progression [4] (level of evidence 1).
he anticancer agent families presently most widely used are
∗ Corresponding author.
E-mail address: jpavillet@chu-grenoble.fr (J. Pavillet).
http://dx.doi.org/10.1016/j.anorl.2015.06.008
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.(1) platins (cisplatin, carboplatin), (2) antimetabolites (5-
ﬂuorouracil, methotrexate), and (3) taxanes (docetaxel, paclitaxel);
these cytotoxins are generally associated to enhance efﬁcacy [5]
(level of evidence 1). For several years now, in some indications,
chemotherapy may  be associated with targeted anti-EGFR anti-
body therapy (cetuximab). Prescription of chemotherapy and
follow-up in head and neck cancer requires particular attention
due to comorbidities related to alcohol abuse and smoking and
denutrition (found in almost half of cases) [6] (level of evidence 2).
Patients are fragile, and management requires close cooperation
between the ENT physician, medical oncologists and radiation
oncologists.
2. Pre-treatment assessment
2.1. Head and neck examination
Complete examination of the upper airways and cervi-
cal lymph-node areas should be performed, using ﬁberoptic
endoscopy (“Initial assessment in head and neck cancer” guideline:
www.orlfrance.org). In laryngeal and hypopharyngeal locations,
vocal fold and arytenoid mobility is to be determined. A signed and
dated diagram of the tumor and lymph-node involvement should
be included in the patient’s medical ﬁle.
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Table  1
Grading A, B or C by decreasing level of evidence according to the French National Health Accreditation and Assessment Agency guide (ANAES) literature assessment and
guidelines grading guide (January 2000).
Correspondence between literature assessment and guidelines grading (adapted Sackett Score)
Level of evidence according to literature Strength of recommendation
Text Position paper Guideline
Level 1
High-power randomized comparative trial
Meta-analysis of randomized comparative trials
Decision analysis founded on well-conducted studies
Grade A
High level of evidence
Level  2
Low-power randomized comparative trial
Well-conducted non-randomized comparative trial
Cohort study
Grade B
Moderate level of evidence
Level 3
Case-control study
Retrospective comparative trial
Level 4
Comparative study with signiﬁcant bias
Retrospective study
Case series
Descriptive epidemiological study (transversal, longitudinal)
Grade C
Low level of evidence
Any  other publication (case report, expert opinion, etc)
No publication
Expert opiniona
Adapted from the French National Health Accreditation and Assessment Agency guide (ANAES) literature assessment and guidelines grading guide (January 2000)
The  present classiﬁcation is intended to clarify the bases on which guidelines are drawn up. Absence of level of evidence should encourage further studies when possible.
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n  pharyngitis, etc).
a Unless otherwise stated, guidelines are based on expert opinion.
.2. Imaging
Morphologic imaging assessment (cervicothoracic CT or head
nd neck MRI) and metabolic imaging (PET-CT) are prescribed to
ssess tumor extension and lymph-node involvement and to screen
or remote secondary sites (mainly lung metastases).
.3. General examination
In the ﬁrst (diagnostic) consultation, the ENT physician should
ssess two points: general health and nutritional status. General
ealth status is assessed on the WHO  criteria (www.antalvite.fr).
s well as prognostic aspects, it is agreed that, except in excep-
ional cases, chemotherapy can only reasonably be indicated in
HO  grades ≤ 2 [1] (level of evidence 4). Nutritional status can
e quickly assessed on simple anthropometric parameters: weight
nd weight change over the previous 6 months [6] (level of evidence
). These data are supplemented by biological assays, and notably
lbuminemia, to calculate a denutrition index, to be reassessed dur-
ng and at end of treatment. Biological assays may  be prescribed by
he ENT physician in the diagnostic consultation. Age as such is
ot a limiting factor, but physiological deterioration of the major
ital functions (cardiac, renal and hepatic) calls for caution in over
0 years old, as treatment toxicity increases, with efﬁcacy that is
ontroversial [7] (level of evidence 2). General health status should
referably be assessed with a geriatrician’s opinion, which should
e requested at the diagnostic consultation. Whatever the patient’s
ge, rigorous interview should look for comorbidities liable to con-
raindicate certain treatments:
cardiovascular pathology (arterial hypertension, coronaropathy,
heart failure);
respiratory failure (COPD and associated infectious complica-
tions);
kidney failure;
hepatocellular and pancreatic failure (cirrhosis, pancreatitis);
diabetes. not relevant or useful (e.g., efﬁcacy of mastectomy in breast cancer, of antibiotics
Biological assays (blood and platelet count, prothrombin, acti-
vated cephalin time, blood ionogram, creatininemia and 24 h
creatinine clearance, transaminases, total bilirubin, alkaline phos-
phatase, gamma-glutamyl transferase) should be prescribed at
diagnostic consultation, and opinion should rapidly be sought from
a cardiologist (notably including echocardiography with estimated
LVEF), pneumologist or other specialist depending on comorbid-
ity, in liaison with the anesthesiologist examining the patient for
diagnostic panendoscopy.
3. Multidisciplinary team meeting
After assessment and collation of all results (histology, imaging,
biology), the patient’s ENT physician should present the ﬁle in a
multidisciplinary team meeting, which may  decide on chemother-
apy, in presence of the ENT physician, medical oncologist, radiation
oncologist and, as applicable, geriatrician. The precise schedule,
taking account of general health status and comorbidity, should
be detailed in the meeting’s report. The possibility of inclusion in a
therapeutic trial should also be speciﬁed.
4. Communication of diagnosis
The consultation to communicate the diagnosis is scheduled
as soon as treatment has been validated in the multidisciplinary
team meeting. The communication is made by the patient’s ENT
physician. The decision to implement treatment by chemotherapy
is taken in a one-on-one interview by the prescribing physician,
who must be a qualiﬁed physician specializing in medical oncol-
ogy or oncologic radiation therapy, or a qualiﬁed ENT specialist
with competence in oncology, or holding a complementary spe-
cialization certiﬁcate in oncology [8] (level of evidence 4). The
type of chemotherapy, number of cycles and duration of treat-
ment should be speciﬁed. Non-speciﬁc toxicity (asthenia, alopecia,
leuko-neutropenia, mucitis, diarrhea) and toxicity speciﬁc to the
treatment molecules should be detailed, if necessary providing the
patient with an information sheet for the treatment plan. A person-
alized care plan is delivered at end of consultation. This medical step
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s followed by a nursing diagnostic communication, with or without
resence of a psychologist according to the patient’s wishes. Con-
ultation with the ENT physician is scheduled, to assess treatment
esponse and decide on continuation of the planned treatment.
. Implementation of chemotherapy
Most chemotherapy schedules require ﬁtting an intravenous
erfusion device, usually an implantable venous access port, under
ocal anesthesia, by a surgeon, radiologist or anesthesiologist [9]
level of evidence 2). Implantation is scheduled at the consultation
o communicate the diagnosis. Chemotherapy may  be started on
he day of implantation, or delayed. Delivery is under the responsi-
ility of a physician with competence in oncology according to the
pproval criteria for the performance of chemotherapy [8] (level
f evidence 4), [10] (level of evidence 4), preferably in a dedi-
ated functional unit [11] (level of evidence 4), in ENT or medical
ncology, or in radiation therapy in case of concomitant radio-
hemotherapy. A document with the telephone number(s) of the
epartment is which treatment is conducted, person to contact
n case of onset of toxicity at home (coordinating nurse) and the
hysician in charge of treatment is provided at start of treatment.
.1. Organ sparing
Organ sparing concerns locally progressive laryngeal and
ypopharyngeal tumors and aims to avoid laryngectomy. Laryn-
eal sparing is therefore considered for stage T3 and T4 laryngeal
nd hypopharyngeal tumors and T2 tumors inaccessible to par-
ial surgery, on condition that the patient accepts the possibility
f salvage surgery in case of insufﬁcient response to induction
hemotherapy. It should not be offered in case of cartilage lysis,
etrocricoid involvement or signiﬁcant subglottic extension. The
eference protocol is TPF (docetaxel, cisplatin, 5-ﬂuorouracil), with
ocetaxel 75 mg/m2/d at D1, cisplatin 75 mg/m2/d at D1 and 5FU
50 mg/m2/d at D1-5, with the cycle repeated (D1 = D21) [2] (level
able 2
anagement steps.
Management step Personnel 
Diagnostic consultation
and
pre-chemotherapy
assessment
ENT physician
Anesthesiologist
Geriatrician
Specialist physicians according to comorbidities
MDTM ENT physician
Medical oncologist
Radiation oncologist
Geriatrician
Radiologist
Pathologist
Consultation to
communicate
diagnosis
Competent or oncology-certiﬁed ENT physician
Medical oncologist
Radiation oncologist
Nurse ± clinical oncopsychologist
Treatment Competent or oncology-certiﬁed ENT physician
Medical oncologist
Radiation oncologist
Follow-up ENT physician (community, hospital)
Medical oncologist
Radiation oncologist
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of evidence 1), [12] (level of evidence 1). This induction schedule
requires strict patient selection to ensure against any contraindi-
cations to this type of treatment: kidney failure, heart failure, etc.
[13] (level of evidence 4). Primary prophylaxis by growth fac-
tors (G-CSF) against febrile neutropenia is strongly recommended.
Most authors recommend 3 cycles, with reassessment of tumor
response at the end of 2 cycles. Only the ENT physician can assess
this response correctly: (1) reduced tumor volume and (2) remo-
bilization of one or both vocal folds and one or both arytenoids,
with objective response corresponding to ≥ 50% reduction in tumor
volume. At the end of the 3rd cycle, clinical examination and mor-
phological imaging are repeated and, if good response (tumoral
response ≥ 50%) is conﬁrmed, radiation therapy is undertaken; if
not, surgery (laryngectomy) is performed. The radiation oncolo-
gist should be informed of response quality as of the 2nd cycle,
so as to be able to plan radiation therapy appointments. Head
and neck examination and reassessment on imaging is sched-
uled 2 months after the end of complete treatment (concomitant
radiation-chemotherapy) to check absence of tumor progression
and also laryngeal function (voice, respiration, swallowing). Subse-
quent surveillance alternates between the ENT physician, medical
oncologist and/or radiation oncologist.
5.2. Concomitant radiation-chemotherapy
Apart from laryngeal sparing schedules, concomitant radiation-
chemotherapy may  be considered for non-operable locally
advanced tumor and, as adjuvant treatment, in case of unfavorable
histologic prognosis. The reference treatment associates radiation
therapy to chemotherapy with cisplatin 100 mg/m2/d at D1, D22
and D43 of radiation therapy [3] (level of evidence 1). In case of
kidney failure in locally advanced non-operable tumor, cisplatin
may  be replaced by cetuximab, a monoclonal anti-EGFR antibody
[14] (level of evidence 1). A1l patients should be re-examined in
ENT 2 months after end of treatment, to check treatment response
quality.
Action(s)
Diagnosis of tumor location
Vocal fold and arytenoid mobility assessment in laryngeal
and/or hypopharyngeal location
General health status (WHO grade) and nutritional status
Comorbidity screening: specialist opinion according to age
(geriatrician) and comorbidity
Biological and radiological examinations
Choice of treatment protocol
Scheduling of consultation to communicate diagnosis
Communication of type of chemotherapy
Specify: duration, number of cycles
Specify speciﬁc and non-speciﬁc toxicities
Appointment for implantable venous access port
Scheduling ENT consultations
Document providing phone number of treatment
department, names and phone numbers of physician and
coordinating nurse, to be contacted in case of toxicity at
home
Supportive care
Clinical examination
Radiologic examinations
Supportive care
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.3. Palliative chemotherapy in local and/or metastatic
ecurrence
Palliative chemotherapy may  be suggested in case of recur-
ence or second location in irradiated territory inaccessible to
ocal treatment, or in metastasis. General health status assessment
WHO grade: performance status) is essential for planning ﬁrst-
ine treatment. In WHO  grade ≤ 2, standard treatment associates
isplatin-5FU-cetuximab, followed by cetuximab maintenance
onotherapy [4] (level of evidence 1). The protocol thus com-
rises 6 cycles (D1 = D21), with cisplatin 100 mg/m2/d at D1, 5FU
000 mg/m2/d from D1 to D4 and cetuximab 250 mg/m2 in a single
eekly dose (initial dose, 400 mg/m2/d at D1 of 1st cycle). Clinical
eassessment in ENT and on imaging is scheduled after 3 cycles.
n case of response or stabilization, 3 further cycles are delivered,
ith clinical and imaging reassessment at the end. If tumoral con-
rol is conﬁrmed, cetuximab alone is continued in maintenance
onotherapy until onset of toxicity and/or new tumoral progres-
ion [15] (level of evidence 2). Cetuximab may  then be administered
ither weekly at 250 mg/m2, or two-weekly at 500 mg/m2. In more
ragile patients, especially with impaired renal function (creatinine
learance < 60 mL/min) or heart failure, the schedule is adapted by
eplacing cisplatin by carboplatin (AUC, 5). Chemotherapy by tax-
nes or methotrexate may  also be considered for fragile patients or
n 2nd line. In WHO  grade ≥ 3, treatment is limited to supportive
are [15] (level of evidence 2).
. Conclusion
Chemotherapy for head and neck cancer requires close coop-
ration between family doctor, ENT specialist, medical oncologist
nd radiation oncologist. For patients aged over 70 years, the opin-
on of a geriatrician is desirable. Treatment response assessment
equires a clinical examination that only the ENT physician can per-
orm, from the point of view of both instrumentation and expertise.
able 2 presents the various steps of management.
It is recommended that the decision to implement chemother-
py should be taken in a one-on-one meeting with the prescribing
hysician, who must be a qualiﬁed specialist in medical oncology
r oncologic radiation therapy, or a qualiﬁed ENT physician with
ompetence in oncology or holding a specialization certiﬁcate in
ncology (expert opinion).
It is recommended that tumor response should be assessed dur-
ng or at end of chemotherapy by an ENT physician (expert opinion).cknowledgments
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